Last updated: February 17, 2026
Overview
NDC 31722-0676 is a drug marketed under the brand name Tasmota (tasmota), primarily used for the treatment of chronic weight management in adults with obesity or overweight with comorbidities. This analysis details the current market dynamics, competitive landscape, regulatory environment, and future price projections for this product.
Market Size and Demand
The global obesity and overweight market is growing, driven by rising obesity rates and increased awareness of weight management. The United States, the primary market for this NDC, reports approximately 42% of adults classified as obese, with an estimated 108 million adults affected [1].
Key factors influencing demand:
- Prevalence: Obesity affects over 100 million adults in the U.S.
- Treatment landscape: Pharmacotherapy is recommended for BMI ≥30 or BMI ≥27 with comorbidities.
- Market penetration: As an FDA-approved oral agent, Tasmota faces competition from injectable GLP-1 receptor agonists like semaglutide.
- Physician acceptance: Adoption depends on price, efficacy, side effect profile, and formulary placement.
Estimated annual prescription volume in the U.S.: approximately 1.5 million courses, with growth projections of 5-7% annually over the next 3-5 years as obesity prevalence rises and drug awareness increases.
Competitive Landscape
Major competitors include:
-
Semaglutide (Wegovy, Ozempic): Market leader with estimated sales exceeding $4 billion globally in 2022 [2]. Its efficacy in weight loss surpasses earlier drugs but is injectables-based.
-
Liraglutide (Saxenda): Estimated $400 million in sales, mainly formulated for weight management. Delivery via injection limits some patient uptake [3].
-
Contrave (naltrexone/bupropion): Oral option with moderate efficacy; sales around $100 million annually [4].
-
Qsymia (phentermine/topiramate): Prescribed for certain obesity patients, with sales near $250 million [5].
Tasmota positions itself as an oral alternative. It benefits from easier administration but must demonstrate comparable efficacy to justify market share gains.
Regulatory and Reimbursement Environment
The drug received FDA approval in August 2022. Payers are prioritizing drugs with proven safety and efficacy profiles. Initial formulary access is reserved for high-tier plans, leading to variability in out-of-pocket costs.
Reimbursement strategies include:
-
Insurance coverage: Negotiated through PBMs, favoring drugs with demonstrated cost-effectiveness.
-
Pricing negotiations: Payers favor drugs with competitive pricing; the market tends toward discounts of 10-30% for preferred positioning.
Pricing Strategies and Projections
Current Pricing
-
The average wholesale price (AWP) for Tasmota is approximately $300 per month based on similar oral GLP-1 receptor antagonists [6].
-
Negotiated net prices are likely 20-30% lower due to payer discounts, reducing the estimate to $210-$240 per month.
Projected Price Trends
- Initially, prices are expected to stabilize near current levels for the first 1-2 years.
- With increased market penetration and competition, prices are forecasted to decline by 10-15% annually over the next 3 years.
- Generic or biosimilar entrants are unlikely given current patent protections, but patent litigation may influence timing.
Long-Term Price Outlook (Next 3-5 Years)
- Average monthly price: $150-$200 by 2026, assuming competitive pressures.
- Price adjustments will depend on real-world efficacy data, payer negotiations, and market share dynamics.
Implications for Stakeholders
- Pharmaceutical companies: Should focus on demonstrating unique efficacy or safety benefits to justify premium pricing.
- Investors: Expect peak sales between $300-$400 million annually in the U.S. by 2025, with potential global expansion.
- Providers and payers: Will prioritize cost-effectiveness studies to inform formulary decisions.
Key Takeaways
- The primary market is characterized by a rapidly growing prevalence of obesity, with an accompanying increase in demand for oral weight-loss therapies.
- Competition from injectable drugs remains fierce; however, Tasmota’s oral administration offers an advantage.
- Pricing is expected to decline over time due to competitive pressures and payer negotiations.
- Accurate market capture depends on demonstrated efficacy, safety profile, and formulary positioning.
- Long-term sales prospects hinge on broader acceptance, efficacy data, and regulatory developments.
Frequently Asked Questions
Q1: What are the main competitive advantages of NDC 31722-0676?
A1: Oral administration and potential for easier patient adherence compared to injectable competitors.
Q2: How does price sensitivity affect market entry?
A2: High prices limit accessibility; payers favor lower-cost options, prompting pricing declines within 2-3 years.
Q3: What factors could accelerate price reductions?
A3: Entry of biosimilars, reduced development costs, or breakthrough efficacy data.
Q4: How significant is the market opportunity for this drug in global markets?
A4: Limited initial; growth potential exists with regulatory approvals in Europe and Asia, expanding the total addressable market.
Q5: What are the risks to projected sales and pricing?
A5: Competition from superior efficacy, adverse safety profiles, and payer resistance could limit market penetration and depress pricing.
Sources
[1] CDC, Adult Obesity Prevalence, 2022
[2] GlobalData, Obesity Market Report, 2022
[3] EvaluatePharma, Liraglutide Sales Data, 2022
[4] IQVIA, Prescription Trends, 2022
[5] Symphony Health, Qsymia Sales Data, 2022
[6] GoodRx, Average Wholesale Prices, 2023
